By Ryan Davis ( April 21, 2015, 9:07 PM EDT) -- An organization tied to hedge fund manager Kyle Bass challenged yet another drug patent Monday, asking the Patent Trial and Appeal Board to invalidate a patent on Pharmacyclics Inc.'s cancer drug Imbruvica, weeks after AbbVie Inc. agreed to buy the company for $21 billion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.